Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study

J José Vicente Gil (Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, 46026 Valencia, Spain, Valencia, Spain) C Claudia Sargas R Rosa Ayala (HOSPITAL 12 DE OCTUBRE, MADRID, Spain) N Norma C. Gutierrez (Hospital Universitario de Salamanca. IBSAL. Centro de Investigación del Cáncer, Salamanca, Spain) J José Antonio Pérez-Simón M María Teresa Gómez-Casares (Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canarias, Spain) M María José Larrayoz (Navarra University Clinic, PAMPLONA, Spain) E Esther Prados de la Torre (University of Cordoba (UCO), Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Hematology Unit, Reina Sofia University Hospital, Córdoba, Spain) I Isabel Cano-Ferri (Hospital Universitari i Politècnic La Fe, Valencia, Spain) I Irene Navarro (Hematology Department, Hospital Universitari i Politècnic, La Fe, Valencia, València, Spain) C Cristina Gil (Hospital Alicante, alicante, Spain) T Teresa Bernal del Castillo (Hospital Universitario Central de Asturias–Instituto Universitario del Principado de Asturias–Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain) E Eduardo Rodríguez-Arbolí (Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, Spain) E Esther Pérez Santaolalla (Hospital Universitario de Donostia, Donostia, Spain) R Rafael Colmenares (Hospital Universitario 12 De Octubre, Madrid, Spain) M Mar Tormo (Hospital Clinico Universitary. INCLIVA Research Institute, Valencia 46010, Spain) J Juan Miguel Bergua Burgues (Hospital San Pedro de Alcántara. Cáceres, Caceres, Spain) M María-Luz Amigo (Hospital Morales Meseguer, Murcia, Spain) C Carlos Rodríguez-Medina (Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain) J Josefina Serrano (University Hospital Reina Sofia. IMIBIC. UCO, Cordoba, Spain) A Ana Oliva (Hospital Virgen de la Candelaria, Tenerife, Spain) J Juan Manuel Alonso-Domínguez (Princess Margaret Cancer Centre, Toronto, Ma, Canada) V Víctor Noriega (Complejo Hospitalario Universitario A Coruña, A Coruña, Spain) J Jesús-Lorenzo Algarra (Hospital General de Albacete, Albacete, Spain) M Mayte T Olave (Hospital Clínico Lozano Blesa. Zaragoza, ZARAGOZA, Spain) M Maria Jose García Perez (Hospital Universitario Torrecárdenas, Almeria, Spain) M María del Carmen Couto (University Hospital Virgen de Valme, Sevilla, Spain) A Agata Almela-Gallego (Leon University Hospital, Leon, Spain) M María García-Fortes (Hospital Universitario Virgen de la Victoria, Málaga, Spain) D Dolores Dolores Madrigal-Toscano (Virgen Macarena University Hospital, Seville, Spain) L Lourdes Hermosín (Servicio Hematología, Hospital de Jerez, Jerez de la Frontera, Jerez de la Frontera, Cadiz, Spain) M Mercedes Colorado (Hospital Universitario Marqués de Valdecilla, Santander, Spain) R Raimundo García-Boyero (Hospital General Universitario de Castellón, Castellón, Spain) F Francisco Ibañez-Alis (Valencia General Hospital, Valencia, Spain) M María Solé-Rodríguez (Department of Haematology of Hospital Juan Ramón Jiménez, Huelva, Huelva, Spain) C Carmen Martinez Chamorro (Hospital Universitario Quironsalud Madrid and Universidad Europea de Madrid, Pozuelo de Alarcon, Spain) M Maria C. Mateos (Complejo Hospitalario de Navarra, Pamplona, Spain) M María del Carmen García Garay (Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain) A Antonio Solana-Altabella (Hospital Universitari i Politècnic La Fe; Dep. of Pharmacy, University of Valencia, Valencia, Spain) B Beatriz Martín-Herreros (Instituto de Investigación Sanitaria La Fe, València, Spain) J Joaquín Martínez-López (Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Madrid Institute of Cancer, Madrid) M M. Carmen Chillon (Hospital Universitario de Salamanca, IBSAL, CIBER-ONC number CB16/12/00233 y Centro de Investigacion del Cancer de Salamanca-IBMCC (USAL-CSIC), Salamanca, Salamanca, Spain) E Elena Soria (Virgen del Rocio University Hospital, Institute of Biomedicine of Seville (IBIS/CSIC), University of Seville, Seville, Spain) C Cristina Bilbao-Sieyro (Hospital Universitario de Gran Canaria Dr. Negrín, Instituto de Investigación Sanitaria de Canarias (IISC), Las Palmas De Gran Canaria, Spain) M Maria J José Calasanz (UNIVERSITY OF NAVARRA, Pamplona, Spain) J Joaquin Sánchez-García (Hospital Universitario Reina Sofía, Córdoba, Spain) E Eva Barragan P Pau Montesinos (Hospital Universitari i Politecnic La Fe, Valencia, Spain)

Abstract

NPM1-mutated acute myeloid leukemia (AML) is genetically well-defined, but clinical outcomes remain heterogeneous, suggesting that quantitative clonal features may refine current risk stratification. We analyzed 688 intensively treated NPM1-mutated AML integrating variant allele frequency (VAF), mutation order, and clonal architecture inferred by PyClone and ClonEvol. Co-mutations were present in 97% of patients (median = 3 per case), dominated by DNMT3A (49%), FLT3-ITD (46%), TET2 (22%), and IDH2 (20%). Prognostic modelling of NPM1 VAF identified an optimal cut-off of 31.44%, defining NPM1high and NPM1low groups. NPM1low correlated with splicing-related alterations and independently predicted inferior overall (HR = 1.46; p = 0.037) and relapse-free survival (HR = 1.40; p = 0.036). Gene-specific VAF analyses revealed divergent effects across partners, high DNMT3A, FLT3-OTHER, KRAS, and PTPN11 burdens were adverse, whereas high IDH2 VAF was protective. Combined models showed that patients with NPM1high and favorable co-mutation VAFs had the best outcomes, while dual unfavorable burdens conferred the poorest survival. Mutation ordering inferred from VAFs positioned NPM1 after epigenetic and splicing lesions but before signaling and transcription-factor mutations. Non-canonical orders, such as early FLT3-OTHER/TKD or WT1 prior to NPM1, significantly stratified outcomes. Clonal reconstruction revealed predominantly linear evolutionary trajectories (84.3%), with increased mutational burden and clonal diversity associating with inferior survival. Notably, intra-clonal co-localization of NPM1 with IDH1 or TET2 was associated with improved outcomes, whereas co-localization with WT1 predicted dismal prognosis. These results demonstrate that quantitative and structural dimensions of clonality refine the biological and prognostic landscape of NPM1-mutated AML beyond mutational status alone.

Article Details

Journal Blood
Volume / Issue Vol. 1, Issue 1
Published June 08, 2026
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (48)

J

José Vicente Gil

Accredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, 46026 Valencia, Spain, Valencia, Spain

C

Claudia Sargas

R

Rosa Ayala

HOSPITAL 12 DE OCTUBRE, MADRID, Spain

N

Norma C. Gutierrez

Hospital Universitario de Salamanca. IBSAL. Centro de Investigación del Cáncer, Salamanca, Spain

J

José Antonio Pérez-Simón

M

María Teresa Gómez-Casares

Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canarias, Spain

M

María José Larrayoz

Navarra University Clinic, PAMPLONA, Spain

E

Esther Prados de la Torre

University of Cordoba (UCO), Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Hematology Unit, Reina Sofia University Hospital, Córdoba, Spain

I

Isabel Cano-Ferri

Hospital Universitari i Politècnic La Fe, Valencia, Spain

I

Irene Navarro

Hematology Department, Hospital Universitari i Politècnic, La Fe, Valencia, València, Spain

C

Cristina Gil

Hospital Alicante, alicante, Spain

T

Teresa Bernal del Castillo

Hospital Universitario Central de Asturias–Instituto Universitario del Principado de Asturias–Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain

E

Eduardo Rodríguez-Arbolí

Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, Spain

E

Esther Pérez Santaolalla

Hospital Universitario de Donostia, Donostia, Spain

R

Rafael Colmenares

Hospital Universitario 12 De Octubre, Madrid, Spain

M

Mar Tormo

Hospital Clinico Universitary. INCLIVA Research Institute, Valencia 46010, Spain

J

Juan Miguel Bergua Burgues

Hospital San Pedro de Alcántara. Cáceres, Caceres, Spain

M

María-Luz Amigo

Hospital Morales Meseguer, Murcia, Spain

C

Carlos Rodríguez-Medina

Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain

J

Josefina Serrano

University Hospital Reina Sofia. IMIBIC. UCO, Cordoba, Spain

A

Ana Oliva

Hospital Virgen de la Candelaria, Tenerife, Spain

J

Juan Manuel Alonso-Domínguez

Princess Margaret Cancer Centre, Toronto, Ma, Canada

V

Víctor Noriega

Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

J

Jesús-Lorenzo Algarra

Hospital General de Albacete, Albacete, Spain

M

Mayte T Olave

Hospital Clínico Lozano Blesa. Zaragoza, ZARAGOZA, Spain

M

Maria Jose García Perez

Hospital Universitario Torrecárdenas, Almeria, Spain

M

María del Carmen Couto

University Hospital Virgen de Valme, Sevilla, Spain

A

Agata Almela-Gallego

Leon University Hospital, Leon, Spain

M

María García-Fortes

Hospital Universitario Virgen de la Victoria, Málaga, Spain

D

Dolores Dolores Madrigal-Toscano

Virgen Macarena University Hospital, Seville, Spain

L

Lourdes Hermosín

Servicio Hematología, Hospital de Jerez, Jerez de la Frontera, Jerez de la Frontera, Cadiz, Spain

M

Mercedes Colorado

Hospital Universitario Marqués de Valdecilla, Santander, Spain

R

Raimundo García-Boyero

Hospital General Universitario de Castellón, Castellón, Spain

F

Francisco Ibañez-Alis

Valencia General Hospital, Valencia, Spain

M

María Solé-Rodríguez

Department of Haematology of Hospital Juan Ramón Jiménez, Huelva, Huelva, Spain

C

Carmen Martinez Chamorro

Hospital Universitario Quironsalud Madrid and Universidad Europea de Madrid, Pozuelo de Alarcon, Spain

M

Maria C. Mateos

Complejo Hospitalario de Navarra, Pamplona, Spain

M

María del Carmen García Garay

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

A

Antonio Solana-Altabella

Hospital Universitari i Politècnic La Fe; Dep. of Pharmacy, University of Valencia, Valencia, Spain

B

Beatriz Martín-Herreros

Instituto de Investigación Sanitaria La Fe, València, Spain

J

Joaquín Martínez-López

Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Madrid Institute of Cancer, Madrid

M

M. Carmen Chillon

Hospital Universitario de Salamanca, IBSAL, CIBER-ONC number CB16/12/00233 y Centro de Investigacion del Cancer de Salamanca-IBMCC (USAL-CSIC), Salamanca, Salamanca, Spain

E

Elena Soria

Virgen del Rocio University Hospital, Institute of Biomedicine of Seville (IBIS/CSIC), University of Seville, Seville, Spain

C

Cristina Bilbao-Sieyro

Hospital Universitario de Gran Canaria Dr. Negrín, Instituto de Investigación Sanitaria de Canarias (IISC), Las Palmas De Gran Canaria, Spain

M

Maria J José Calasanz

UNIVERSITY OF NAVARRA, Pamplona, Spain

J

Joaquin Sánchez-García

Hospital Universitario Reina Sofía, Córdoba, Spain

E

Eva Barragan

P

Pau Montesinos

Hospital Universitari i Politecnic La Fe, Valencia, Spain